Miller Edward's Form 4 filing
Kalaris Therapeutics, Inc. (KLRS) · filed Jan 23, 2023
- Accession no.
- 0001209191-23-004501
- Filed
- Jan 23, 2023
- Trade date
- Dec 2, 2022-Jan 20, 2023
- Filing delay
- 52 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $13.1K. It was filed 52 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Miller EdwardCIK 0001619252 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2022 | Common Stock | GGiftDisposed | −98,346 | $0.00 | $0 | 151,031 | Direct | |
| Dec 2, 2022 | Common Stock | GGiftAcquired | +98,346 | $0.00 | $0 | 288,799 | Indirect | |
| Jan 19, 2023 | Common Stock | SSaleDisposed | −2,032 | $5.08F4 | −$10,322.56 | 148,999 | Direct | |
| Jan 20, 2023 | Common Stock | SSaleDisposed | −541 | $5.14F5 | −$2,780.74 | 148,458 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.05 to $5.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.